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Subunits of the SWI/SNF chromatin remodeling
complex are mutated in a significant proportion
of human cancers. Malignant rhabdoid tumors
(MRTs) are lethal pediatric cancers characterized
by a deficiency in the SWI/SNF subunit SMARCB1.
Here, we employ an integrated molecular profiling
and chemical biology approach to demonstrate
that the receptor tyrosine kinases (RTKs) PDGFRa
and FGFR1 are coactivated in MRT cells and
that dual blockade of these receptors has syner-
gistic efficacy. Inhibitor combinations targeting
both receptors and the dual inhibitor ponatinib
suppress the AKT and ERK1/2 pathways leading
to apoptosis. MRT cells that have acquired resis-
tance to the PDGFRa inhibitor pazopanib are
susceptible to FGFR inhibitors. We show that
PDGFRa levels are regulated by SMARCB1 expres-
sion, and assessment of clinical specimens docu-
ments the expression of both PDGFRa and FGFR1
in rhabdoid tumor patients. Our findings support
a therapeutic approach in cancers with SWI/SNF
deficiencies by exploiting RTK coactivation depen-
dencies.INTRODUCTION
Inactivating mutations in genes encoding components of the
SWI/SNF chromatin remodeling complex are found in 20% of
cancers (Kadoch et al., 2013). Treatment of this class of tumors
is challenging and there are currently no targeted therapies
approved for clinical use. The prototypical example of this class
is the malignant rhabdoid tumors (MRTs), which are rare pediat-Cell Rep
This is an open access article undric cancers of the kidney and soft tissues. MRTs are character-
ized by the biallelic inactivation of the SMARCB1 (INI1/SNF5/
BAF47) gene, which encodes a core component of the SWI/
SNF complex and is a tumor suppressor (Kim and Roberts,
2014).
In addition to the MRTs, atypical teratoid/rhabdoid tumors
(AT/RTs) are rhabdoid tumors of the CNS that are similarly char-
acterized by the loss of SMARCB1 (Fr€uhwald et al., 2016). MRTs
are highly aggressive, and, despite intensive multimodal ther-
apy, prognosis remains dismal with many children not surviving
beyond 12 months (Madigan et al., 2007). SMARCB1 mutation
is the sole driver of disease, and MRTs and AT/RTs lack
additional gene amplifications or deletions and demonstrate
low rates of mutations (Chun et al., 2016; Johann et al., 2016;
Lee et al., 2012). The mechanisms by which SMARCB1 loss
contributes to tumor progression are not fully understood, and
analyses of genes regulated by SMARCB1 have revealed
several candidate oncogenes, including components of the
cell cycle machinery, sonic hedgehog pathway, and canonical
Wnt signaling (Kim and Roberts, 2014). Identifying the funda-
mental oncogenic drivers resulting from SMARCB1 deficiency
remains a significant challenge and a key barrier to developing
effective therapies.
Receptor tyrosine kinases (RTKs) are attractive targets for
cancer therapy with several tyrosine kinase inhibitors (TKIs) clin-
ically approved for a range of tumor types (Lemmon and Schles-
singer, 2010). We and others have shown that cancer cells rely
on the activation of multiple RTKs to maintain robust oncogenic
signaling (Huang et al., 2007). Employing TKI combinations is
effective in overcoming compensatory RTK signaling and ulti-
mately killing cancer cells (Xu and Huang, 2010). In this study,
we utilize an integrated molecular profiling and chemical biology
approach to show that MRT cells display coactivation of
PDGFRa and FGFR1 and that therapeutic inhibition of both
RTKs leads to synergistic cytotoxicity. Our findings demonstrate
that exploiting RTK coactivation dependencies may be benefi-
cial in the treatment of cancers with SWI/SNF deficiencies.orts 17, 1265–1275, October 25, 2016 ª 2016 The Author(s). 1265
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
RESULTS
MRT Cell Lines Are Selectively Responsive to Dasatinib,
Pazopanib, and Sunitinib
The TKIs dasatinib, pazopanib, and sunitinib are either approved
or currently being evaluated for soft tissuemalignancies, such as
sarcomas and MRTs. To identify subtypes that may be selec-
tively responsive to these TKIs, a panel of 14 sarcoma and
MRT lines were subjected to dose-response assessment. Only
the MRT cell lines A204 and G402 were found to be sensitive
to all three TKIs (Figure 1A; Table S1).
Analysis of Acquired Resistance Identifies PDGFRa as
an Oncogenic Driver in MRT Cells
Durable responses to TKIs are rare and most patients develop
acquired drug resistance (Kasper et al., 2014). To discover po-
tential resistance mechanisms, we modeled acquired resistance
in vitro by subjecting the A204 cells to long-term escalating dose
treatment with each of the three TKIs. Cell viability analysis
confirmed that these sublines have acquired resistance and
were cross-resistant to each other (Figure 1B; Table S1), sug-
gesting a common mechanism of action.
To identify candidate kinases that confer TKI sensitivity, we
assessed the target selectivity overlap among the three inhibi-
tors based on published screens of TKI selectivity (Anastassiadis
et al., 2011; Davis et al., 2011). Pazopanib, dasatinib, and suniti-
nib share three common RTK targets, KIT, CSF1R, and PDGFRa
(Figure 1C), of which only PDGFRa is activated in the A204 cells
as shown by a previous phosphoproteomic screen (Bai et al.,
2012). Immunoblotting revealed a reduction in PDGFRa expres-
sion in the acquired resistant sublines (Figure 1D), indicating that
a loss in PDGFRa pathway dependency is a potential mecha-
nism of drug resistance.
Treatment of the parental A204 cells with the three TKIs led to
a decrease in PDGFRa phosphorylation (Figure 1E). Further-
more, small interfering RNA (siRNA) depletion of PDGFRa was
able to phenocopy the TKI effects and decrease MRT cell
viability (Figures 1F and 1G). Immunoblot analysis of down-
stream signaling components AKT and ERK1/2, which control
cell proliferation and survival, showed that the TKIs abolished
AKT phosphorylation but had no effect on ERK1/2 phosphoryla-
tion in the parental cells (Figure 1H). Upon ectopic expression of
SMARCB1 in the MRT cells, PDGFRa levels were decreased
compared to control (Figure 1I), demonstrating that SMARCB1
regulates PDGFRa expression. Collectively, our findings show
that PDFGRa is a driver in MRT cells that is regulated by
SMARCB1 and can be effectively inhibited using pazopanib, da-
satinib, and sunitinib.
Molecular Profiling of A204 Parental and Resistant Cells
To identify additional candidate drivers in MRTs, we undertook
a molecular profiling strategy comprising microarray-based
comparative genomic hybridization (aCGH), gene expression
analysis, and phosphoproteomics, using the A204 parental and
three resistant sublines as a model. The aCGH was performed
to assess chromosomal gains or losses associated with ac-
quired resistance. The A204 cells have a simple genome with
no detectable chromosomal alterations other than a focal dele-1266 Cell Reports 17, 1265–1275, October 25, 2016tion of SMARCB1 at 22q11.23 (Figures 2A and S1A), which is
maintained in the resistant sublines. Of the resistant cells, only
the dasatinib-resistant (DasR) subline harbored additional gains
on chromosome 17q21.32-q25.3 and losses of the whole arm of
13q (Figure 2A). Since this genomic profile was specific to DasR,
it is unlikely that any targets identified in these chromosomal re-
gions would be common to all three TKIs and, thus, were not pur-
sued further. Gene expression analysis of the four cell lines in the
presence of TKI showed that the resistant sublines clustered
together with the untreated parental cells (Figure S1B), and it
confirmed that PDGFRA was among the most highly downregu-
lated genes in the resistant cells (Figures 2B and S1C).
Phosphoproteomics was used to compare the signaling pro-
files of DasR and pazopanib-resistant (PazR) sublines versus
parental cells. Sunitinib-resistant (SunR) cells were not analyzed
because their low proliferation rate prevented sufficient cells
from being harvested. We show that parental cells displayed
high levels of phosphorylated PDGFRa at multiple sites (Y613,
Y742, Y762, Y768, and Y849) (Figure 2C). Interestingly, FGFR1
phosphorylation in the kinase insert domain (Y583 and Y585)
also was found to be elevated in the parental cells. Additionally,
FGFR1 was phosphorylated in its activation loop (Y653 and
Y654) at similar levels in both parental and resistant cells. These
data confirm that PDGFRa is the only common kinase target of
pazopanib, dasatinib, and sunitinib that is activated in these cells
(Figure 1C), and they demonstrate that both PDGFRa and
FGFR1 are coactivated with multiple phosphosites observed in
each receptor.
Dual Targeting of PDGFRa and FGFR1 Enhances
Apoptosis
Since FGFR1 phosphorylation was uncovered in our phospho-
proteomic analysis, coupled with a previous report that FGFR
RTKs are therapeutic targets in MRTs (Wo¨hrle et al., 2013), we
reasoned that a combination of PDGFRa and FGFR inhibitors
may have enhanced efficacy. We first assessed the effects of
two selective FGFR TKIs NVP-BGJ398 and AZD4547 on the
viability of A204 and G402 cells (Tan et al., 2014). AZD4547
was ineffective in both cell lines while BGJ398 only reduced
viability in the A204 cells (Figure 3A). As a positive control,
AN3CA cells that harbor an FGFR2 mutation and are sensitive
to FGFR TKIs were used (Tan et al., 2014). Depletion of FGFR1
using siRNA also showed a minor decrease in the viability of
the MRT cells (Figures 3B and 3C).
We evaluated the effects of BGJ398 and AZD4547 in combi-
nation with PDGFRa TKIs on cell viability and apoptosis. This
combination showed a small decrease in A204 andG402 viability
compared to single inhibitor treatment (Figure S2A), reflecting
the strong cytostatic consequence of PDGFRa TKI monotherapy
(Figure 1A). Assessment of caspase 3/7 activity found that
PDGFRa or FGFR TKI treatment alone led to low levels of
apoptosis despite high drug concentrations of up to 1 mM (Fig-
ures 3D and S2B). Dual PDGFRa and FGFR inhibition showed
significantly increased apoptosis (>6-fold relative to vehicle
control). This enhanced apoptosis was recapitulated with a com-
bination of siRNA depletion of PDGFRa andBGJ398 or AZD4547
treatment (Figure S2C). To assess if the combination confers
synergistic cytotoxicity in the A204 cells, we employed an
Figure 1. MRT Cell Lines Are Sensitive to PDGFRa Inhibitors
(A) Dose-response curves of dasatinib-, pazopanib-, and sunitinib-resistant (black) and -sensitive (red) cell lines. A panel of 14 cell lines was treatedwith a range of
drug concentrations to determine IC50 values (Table S1). Cell viability is normalized to DMSO control (n = 2 or 3).
(B) Dose-response curves of TKI-resistant sublines (black) and parental A204 cells (red). IC50 values are detailed in Table S1. Cell viability is normalized to DMSO
control (n = 3).
(C) Target selectivity overlap plot of dasatinib, pazopanib, and sunitinib shows that KIT, CSF1R, and PDGFRa are common targets.
(D) Immunoblot of PDGFRa expression in parental A204 and resistant sublines is shown. DasR, dasatinib resistant; PazR, pazopanib resistant; SunR, sunitinib
resistant.
(E) Immunoprecipitation of PDGFRa followed by immunoblotting with phosphotyrosine-specific antibody (PY1000) shows a decrease in receptor phosphory-
lation with 1 mM TKI for 1 hr.
(F) Immunoblot of PDGFRa expression in the MRT cells under mock, non-targeting control siCONT and siPDGFRa pool transfection conditions is shown.
(G) Bar plots showing cell viability of MRT cells upon siRNA silencing of PDGFRa. Cell viability data are normalized tomock transfection (n = 3). Statistical analysis
of siPDGFRa versus siCONT was performed by paired Student’s t test (*p < 0.05).
(H) Immunoblot of AKT and ERK1/2 phosphorylation levels in A204 cells treated with TKIs at the indicated doses for 3 hr is shown.
(I) Immunoblot of PDGFRa shows downregulation of receptor levels upon ectopic SMARCB1 expression.
For (A), (B), and (G), all values are mean ± SD.automated imaging assay to visualize annexin V-positive cells.
While the individual TKIs only resulted in <5% apoptotic cells
(Figure S2D), the combination of BGJ398 with either pazopanibor dasatinib led to a synergistic increase (combination index < 1)
in the proportion of apoptotic cells to30%–50%across all drug
doses tested (Figures 3E and S2D).Cell Reports 17, 1265–1275, October 25, 2016 1267
Figure 2. Molecular Profiling of A204 Cells
(A) aCGH plots of A204 parental and resistant cells. Selected profiles of chromosome 22 illustrate focal deletion of SMARCB1 in 22q11.23. DasR harbors
chromosome 17 and 13 alterations, illustrating gains (green) and losses (red), respectively. Full genomic profiles are presented in Figure S1A.
(legend continued on next page)
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To establish if a dual inhibitor of both receptors is capable of
inducing apoptosis as a single agent, the effects of ponatinib,
a potent inhibitor of FGFR1 and PDGFRa (Gozgit et al., 2011),
were investigated. While previous reports claim that pazopanib
and sunitinib are FGFR1 inhibitors, the KD of these compounds
for FGFR1 are 128-fold and 67-fold higher, respectively,
compared to ponatinib (Tucker et al., 2014). Assessing the
dose-response effects of ponatinib in the panel of 17 cell lines,
consisting of five SMARCB1-deficient cell lines (A204, G402,
G401, BT12, and CHLA226) and 12 wild-type sarcoma cell lines,
confirmed that cells with SMARCB1 deficiency were sensitive to
this TKI (Figure 3F). Treatment with ponatinib resulted in
enhanced apoptosis in the A204 and G402 MRT cells, at levels
similar to combined PDGFRa and FGFR TKI treatment (Figures
3G and S2E).
In contrast to the PDGFRa TKIs, FGFR inhibitor (BGJ398)
treatment had no effect on AKT phosphorylation but instead
decreased ERK1/2 phosphorylation (Figure 3H). As expected,
BGJ398 had no effects on PDGFRa phosphorylation (Fig-
ure S2F). Correspondingly, combined treatment with PDGFRa
and FGFR TKIs or ponatinib resulted in the suppression of
both ERK1/2 and AKT phosphorylation (Figure 3H), consistent
with a model where inhibition of both pathways is required for
inducing apoptosis in MRT cells. To test this hypothesis, we
treated the A204 cells with the PI3K/mTOR inhibitor NVP-
BEZ235, the MEK inhibitor trametinib, and a combination of
both inhibitors to block the AKT and ERK1/2 pathways, respec-
tively. Immunoblotting confirmed that these pathways were
suppressed upon inhibitor treatment (Figure 3I). Similar to
PDGFRa inhibitor monotherapy (Figures 1A and S2A), treatment
with BEZ235 alone led to a decrease in cell viability (Figure 3J)
but had limited effects on apoptosis (Figure 3K). Treatment
with trametinib alone was ineffective in reducing cell viability
(Figure 3I), which is consistent with FGFR inhibitor monotherapy
data (Figure 3A). Combined treatment of BEZ235 and trametinib
recapitulates the elevated apoptosis levels (Figure 3K) observed
with ponatinib or PDGFRa and FGFR inhibitor combinations (Fig-
ures 3D and 3G). Collectively our data provide additional support
that MRTs cells require both the AKT and ERK1/2 pathways for
cell survival.
FGFR Inhibitors Sensitize MRT Cells that Have Acquired
Resistance to Pazopanib
Given that pazopanib is approved for soft tissue malignancies
and there is currently no effective means to treat patients whose
tumors have progressed on this TKI, we investigated if targeting
FGFR1 is capable of sensitizing cells that have acquired pazopa-
nib resistance. The resistant sublines maintain FGFR1 expres-
sion (Figure S3A) and activation loop phosphorylation (Figure 2C)
at levels similar to the parental cells. Treating PazR cells with
BGJ398 led to a reduction in cell viability that was not enhanced
by the addition of pazopanib, demonstrating that these cells are(B) Heatmap of the top 50 downregulated genes in the resistant sublines versu
presented in Figure S1B.
(C) Heatmap of phosphoproteomic data with log2 fold change of untreated A204 p
and FGFR1 phosphorylation sites highlighted in red and blue, respectively. Gra
condition. Data presented are an average of three independent experiments.no longer addicted to PDGFRa (Figure 3L; Table S2). The degree
of sensitization of the PazR cells in response to BGJ398 was
similar to the IC50 of pazopanib treatment in the parental A204
cells (Table S1). Pazopanib alone had no effect on apoptosis
compared to vehicle control, while BGJ398, ponatinib, or the
combination of BGJ398 and pazopanib led to a significant in-
crease in the proportion of apoptotic cells (Figure 3M). These
data demonstrate that FGFR1 blockade is an effective means
of overcoming resistance to pazopanib.
Since the AKT pathway is inhibited by pazopanib via PDGFRa
blockade (Figure 3H), we sought to determine if bypass of the
requirement for the AKT pathway is a potential mechanism of pa-
zopanib resistance. In the absence of pazopanib, PazR cells
maintained a reduced level of AKT phosphorylation (compared
to parental A204 cells), which decreased upon treatment with
pazopanib, while FGFR1 blockade did not reduce AKT phos-
phorylation levels (Figure S3B). Treatment of PazR cells with
BEZ235 abolished AKT phosphorylation (Figure S3C). Dose-
response measurements showed that PazR cells were more
resistant to BEZ235 treatment compared with parental A204
cells, with a >3-fold increase in IC50 values (Figure S3D). In
addition, BEZ235 treatment in PazR cells did not lead to a statis-
tically significant increase in apoptosis levels compared to
parental A204 cells (Figure S3E). These data demonstrate that
one potential mechanism of pazopanib resistance in the PazR
cells is a reduced requirement for the AKT pathway for cell
survival.
In some cancers, subpopulations of cancer cells displaymutu-
ally exclusive RTK amplification events reflecting intratumoral
heterogeneity, and clonal selection during therapy leads to ac-
quired resistance (Szerlip et al., 2012). Previous fluorescence
in situ hybridization (FISH) analysis of A204 cells found that
PDGFRa was not amplified at the genomic level (McDermott
et al., 2009). To establish if heterogeneity in RTK expression
could be a potential mechanism for drug resistance, immunoflu-
orescence was performed to determine the distribution of
PDGFRa and FGFR1. We found that both RTKs were expressed
in all cells within the parental A204 population (Figure S3F), and,
consistent with the immunoblot data, the three resistant sublines
displayed reduced PDGFRa levels and maintained FGFR1
expression. These data confirm that RTK expression is notmutu-
ally exclusive in distinct subpopulations, and they suggest that
acquired resistance is unlikely the result of clonal selection of a
pre-existing PDGFRa-deficient subpopulation but rather the
consequence of genetic evolution by PDGFRa loss in drug-
tolerant cells during TKI selection (Hata et al., 2016).
PDGFRA and FGFR1 Are Expressed in Rhabdoid Tumor
Patients
To verify the clinical relevance of our findings, we evaluated the
mRNA levels of PDGFRA and FGFR1 in an RNA sequencing
(RNA-seq) dataset of 23 primary rhabdoid tumor (RT) patients the parental A204 cells treated with TKIs. Full gene expression dataset is
arental cells versus DasR or PazR in the presence of TKI versus with PDGFRa
y boxes represent phosphosites that were not observed under that specific
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specimens composed of 12 MRTs and 11 AT/RTs. RNA-seq
data from 172 normal tissue samples from the Illumina Bodymap
were used as controls. Read count data in RT samples showed
an average of 2,514 and 12,127 normalized reads mapped to
PDGFRA and FGFR1, respectively, indicating moderate-high
expression of each gene. Average levels of expression were
significantly higher in RT than in the normal tissue collection for
PDGFRA (p = 0.016) and FGFR1 (p < 0.001). Indeed, a substan-
tial number of RT samples (35% and 70%of primary RT samples
for PDGFRA and FGFR1, respectively) showed greater expres-
sion than the 95th percentile of normal tissue samples for these
genes, implying a large degree of tumorigenic overexpression
(Figure 4A; Table S3).
Immunohistochemistry was performed on two MRT and two
AT/RT cases to determine PDGFRa and FGFR1 protein expres-
sion levels (Figures 4B and S4). All cases showed no nuclear
staining for SMARCB1. FGFR1 stained positively in the cyto-
plasm in three of four cases, and in both MRT specimens
(NMB957 and NMB997) additional membrane staining was
observed. PDGFRawas expressed in all four RT caseswith cyto-
plasmic staining in tumor cells. As a comparison, we assessed
two medulloblastoma cases (NMB361 and NMB795), which
showed nuclear staining for SMARCB1 and were negative for
both PDGFRa and FGFR1 (Figure 4B). These findings support
the RNA-seq analysis and confirm that both PDGFRa and
FGFR1 are expressed in RT patient specimens.
DISCUSSION
MRTs are often lethal within the first year of diagnosis and many
patients are refractory to standard chemotherapy (Madigan
et al., 2007). There is thus an urgent need for new effective ther-
apies. This study demonstrates that dual inhibition of PDGFRa
and FGFR1 leads to suppression of AKT and ERK1/2 phosphor-Figure 3. Dual Inhibition of PDGFRa and FGFR1 Is Cytotoxic in MRT C
(A) Dose-response curves for MRT and AN3CA cell lines upon treatment with
control (n = 3).
(B) Immunoblot of FGFR1 expression in MRT cells under mock, non-targeting co
(C) Bar plots showing cell viability ofMRT cells upon siRNA silencing of FGFR1. Ce
siFGFR1 versus siCONT was performed by paired Student’s t test (**p < 0.01; N
(D) Bar plots showing the normalized fold change in caspase 3/7 activity in the
indicated doses (n = 3). Data for G402 cells are presented in Figure S2B. Data a
single TKI treatment was done by ANOVA with Tukey’s multiple comparison test
(E) Combination index (CI) measurements for BGJ398 and PDGFRa inhibitors i
response measurements are presented in Figure S2D.
(F) Log2 IC50 values of SMARCB1-deficient (n = 5) versus wild-type (n = 12) cell line
range of ponatinib concentrations. Cell viability is normalized to DMSO control (n
(G) Bar plots showing the normalized fold change in caspase 3/7 activity in the A2
control. Statistical analysis was performed by paired Student’s t test (*p < 0.05).
(H) Immunoblot of AKT and ERK1/2 phosphorylation levels in A204 cells upon dr
(I) Immunoblot of AKT and ERK1/2 phosphorylation levels in A204 cells upon dru
(J) Dose-response curves for A204 cells treated with BEZ235, trametinib, and a
(K) Bar plots showing the normalized fold change in caspase 3/7 activity in the A20
(n = 3). Statistical analysis between combination and single kinase inhibitor treat
(L) Dose-response curves for PazR cells treated with pazopanib, BGJ398, a comb
IC50 values are detailed in Table S2.
(M) Bar plots showing percentage of annexin V staining in PazR cells treated w
Statistical analysis of TKI treatment versus DMSO was done by paired Student’s
Data presented for (A), (C), (D), (F), (G), (J), (K), (L), and (M) are means ± SD.ylation, resulting in synergistic cytotoxicity inMRT cells. Previous
reports have found that A204 cells are sensitive to sunitinib
and dasatinib (albeit mislabeled as a rhabdomyosarcoma line)
through the inhibition of PDGFRa (Bai et al., 2012; McDermott
et al., 2009). The FGFR inhibitor BGJ398 also has been shown
to reduce MRT cell growth (Wo¨hrle et al., 2013). However, our
experiments find that these inhibitors have limited utility as single
agents and do not induce apoptosis. Dual blockade of both
RTKs promotes cytotoxicity across all drug doses tested in
A204 and G402 cells. While TKI combinations may display better
efficacy, there is a risk of greater toxicities. We show that pona-
tinib, a dual PDGFRa and FGFR1 inhibitor, induces apoptosis in
MRT cells as a single agent. Given that our data document the
expression of both PDGFRa and FGFR1 in RT patient speci-
mens, we posit that ponatinib is a candidate for further evalua-
tion in the treatment of RT patients. It should be noted that
additional pre-clinical work in in vivo models is required to deter-
mine the therapeutic window of ponatinib or dual inhibition of
PDGFRa and FGFR1 in order to take this therapeutic strategy
further into clinical trials.
Our findings have implications for other cancer types that har-
bor SMARCB1 deficiencies, including epithelioid sarcomas,
renal medullary carcinoma, epithelioid malignant peripheral
nerve sheath tumors, and extraskeletal myxoid chondrosarco-
mas (Margol and Judkins, 2014). The SS18-SSX fusion in
synovial sarcoma is known to disrupt the SWI/SNF assembly, re-
sulting in SMARCB1-deficient complexes (Kadoch and Crab-
tree, 2013). Furthermore, reduced SMARCB1 protein expression
is found in a proportion of synovial sarcomas (Margol and Jud-
kins, 2014). Our data indicate that it may be beneficial to assess
PDGFRa and FGFR1 levels to determine if ponatinib has similar
efficacy in these cancers.
Mutations in SWI/SNF subunits are found in 20% of cancers
(Kadoch et al., 2013). It was reported recently that EGFRells
FGFR inhibitors BGJ398 and AZD4547. Cell viability is normalized to DMSO
ntrol siCONT and siFGFR1 pool transfection conditions is shown.
ll viability data are normalized tomock transfection (n = 3). Statistical analysis of
S, not significant).
A204 cells treated with PDGFRa and FGFR inhibitors or a combination at the
re normalized to DMSO control. Statistical analysis between combination and
(***p < 0.001).
n A204 cells show synergy (CI < 1) across all doses tested. Individual dose-
s in response to ponatinib treatment. A panel of 17 cell lines was treated with a
= 2). Statistical analysis was performed by paired Student’s t test.
04 and G402 cells treated with ponatinib (n = 3). Data are normalized to DMSO
ug treatment with TKI at the 1 mM dose for 1 hr is shown.
g treatment with BEZ235 and trametinib at the 1 mM dose for 1 hr is shown.
combination of both. Cell viability is normalized to DMSO control (n = 3).
4 cells treatedwith BEZ235, trametinib, or a combination at the indicated doses
ment was performed by paired Student’s t test (*p < 0.05 and **p < 0.01).
ination of both, or ponatinib. Cell viability is normalized to DMSO control (n = 3).
ith pazopanib, BGJ398, a combination of both inhibitors, or ponatinib (n = 3).
t test (*p < 0.05 and **p < 0.01; NS, not significant).
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expression is regulated by SMARCE1, SMARCA4, and ARID1A
and that SMARCE1 deficiency confers TKI resistance in lung
cancer (Papadakis et al., 2015). Wo¨hrle et al. (2013) showed
that FGFR1 is upregulated when SMARCB1 is deleted in MRT
cells, while Darr et al. (2015) recently demonstrated that EGFR
expression is regulated by SMARCB1. In our experiments,
ectopic expression of SMARCB1 in MRT cells show that
FGFR1 and EGFR are only regulated by SMARCB1 in the A204
cells and not the G402 line (Figure S2G), suggesting that there
may be some context specificity associated with the regulation
of RTK expression levels by SMARCB1. By showing that
SMARCB1 loss also regulates PDGFRa expression levels, our
study provides further evidence that exploiting RTK depen-
dencies in cancers driven by SWI/SNF deficiencies is an effec-
tive therapeutic strategy in vitro. Since it is currently not possible
to directly target the SWI/SNF complex, TKI combinations may
have broader clinical utility in the treatment of this class of
cancers.
Acquired resistance and tumor recurrence is common in pa-
tients undergoing TKI therapy. Pazopanib is approved for sar-
coma treatment, but patients eventually develop resistance by
mechanisms that are unknown (Kasper et al., 2014). Our study
presents one mechanism of acquired resistance to pazopanib
in soft tissue malignancies through PDGFRa loss and bypass
of the AKT-signaling pathway, and it provides a means to over-
come this resistance via FGFR1 blockade in vitro. Since it is
less likely for cancer cells to develop acquired resistance when
multiple RTKs are simultaneously inhibited up front, there is a
rationale for using the PDGFRa and FGFR1 inhibitor combination
as first-line therapy (Tan et al., 2016). Indeed, attempts by our
laboratory to generate acquired resistant lines to the PDGFRa
and FGFR inhibitor combination have been unsuccessful (Fig-
ure S2H). Determination of FGFR1 levels in patients who develop
resistance to pazopanib may stratify cases that could benefit
from subsequent therapy with FGFR inhibitors. There remain
several outstanding questions that need to be addressed in
future studies, such as specifically how PDGFRa is downregu-
lated in the PazR cells and what the mechanism is by which
FGFR1 blockade overcomes resistance. Phosphoproteomic
analysis of the PazR cells revealed candidate pathways such
as PLCG1 and Src family kinases (YES1, FYN, and FGR), which
are upregulated. These proteins serve as targets for future eval-
uation as additional means to overcome acquired pazopanib
resistance.
In summary, we show that MRTs are exquisitely sensitive to
the combined inhibition of PDGFRa and FGFR1 and that ponati-
nib is effective as a single agent in this disease in the in vitro
setting. A previous chemical inhibitor screen in AT/RT cell lines
found that the PDGFRa and FGFR inhibitors were not effective
in reducing cell viability (Singh et al., 2013), highlighting theFigure 4. PDGFRa and FGFR1 Are Expressed in Rhabdoid Tumor Patie
(A) Relative RNA expression levels of PDGFRA and FGFR1 genes between rhab
stabilized transformed expression across the samples. Boxplots show median sc
Boxplots are ordered according to median expression level and RT is highlighted
The horizontal line represents the 95th percentile of all normal tissues for each ge
(B) Immunohistochemical analysis of MRT andmedulloblastoma (MB) patient spe
bar represents 0.2 mm.complexity of cell-type-specific signaling dependencies in
SMARCB1-deficient cell lines. Given the recent identification of
distinct epigenetic subgroups in AT/RTs (Johann et al., 2016),
future work will need to establish if PDGFRa and FGFR
dependencies are linked to specific molecular subgroups in
SMARCB1-deficient tumors. We also find that treatment with
FGFR inhibitors sensitizes MRT cells that have acquired resis-
tance to pazopanib. This study provides proof-of-principle that
exploiting RTK co-activation dependencies may have utility in
the treatment of cancers with deficiencies in SWI/SNF subunits.
EXPERIMENTAL PROCEDURES
Cell Culture
A204, G402, and G401 cells were obtained from ATCC. CHLA226 and BT12
cells were provided by the Children’s Oncology Group Cell Culture Repository.
All other lines were a gift from Dr. Janet Shipley. Details for cell culture condi-
tions and derivation of acquired resistant sublines are described in the Supple-
mental Experimental Procedures.
Molecular Biology and Lentiviral Infection
The procedure for ectopic expression of SMARCB1 by lentiviral infection is
detailed in the Supplemental Experimental Procedures.
Immunoblotting, Immunoprecipitation, and Immunofluorescence
After the indicated treatments, cells were lysed in radio-immunoprecipitation
assay (RIPA) lysis buffer at 4C. Lysates were loaded onto SDS-PAGE gels fol-
lowed by blotting onto polyvinylidene fluoride (PVDF) membranes. Details of
antibodies and immunoprecipitation and immunofluorescence analyses are
presented in the Supplemental Experimental Procedures.
Cell Viability and Apoptosis Assays
Cells (2,000/well) were seeded in a 96-well plate, and they were treated with
inhibitors at the indicated dose and combinations for 24 hr for apoptosis
measurement by Caspase-Glo 3/7 Assay (Promega) or for 72 hr in cell viability
measurements by WST-1 (Abcam), following the manufacturer’s recommen-
dations. IC50 data were generated from dose-response curves fitted using a
four-parameter regression fit in PRISM 5 software (GraphPad). Details for
annexin V staining and siRNA transfections are given in the Supplemental
Experimental Procedures.
aCGH, Gene Expression, and Phosphoproteomic Analysis
Genomic DNA was extracted and analyzed on an in-house aCGH platform
consisting of 32,000 bacterial artificial clones (BACs) tiled across the
genome. Descriptions of platform and data analysis procedure are provided
in the Supplemental Experimental Procedures. RNA was extracted and gene
expression analysis was performed on Illumina HTv12 chip as per the manu-
facturer’s recommendations. Data analysis methodology is presented in the
Supplemental Experimental Procedures. Phosphoproteomic analysis was
performed as described (Iwai et al., 2013), with the modifications in protocol
and bioinformatic analysis as detailed in the Supplemental Experimental
Procedures.
RNA-Seq and Immunohistochemistry of Patient Specimens
Human tumor samples were provided by the UK CCLG as part of CCLG-
approved biological study (2012 BS 05). Informed consent was obtainednt Specimens
doid tumors (RTs) and various normal tissues. Boxplots show log2 variance-
ore (thick black line), interquartile ranges (extent of box), and range (whiskers).
in red. The p values indicate one-sided t test between RT and normal tissues.
ne. RNA expression data are provided in Table S3.
cimens for H&E, anti-SMARCB1, anti-PDGFRa, and anti-FGFR1 staining. Scale
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from all subjects. Human tumor investigations were conducted with approval
from Newcastle/North Tyneside Research Ethics Committee (study reference
07/Q0905/71). RNA was extracted from 23 fresh frozen tumor tissue samples
taken from pediatric patients with a confirmed diagnosis of SMARCB1
negative RT. A paired-end cDNA sequencing library was created and
sequenced on an Illumina Hi-Seq2500 to give 90 M paired-end reads.
Reads were quality checked, aligned, and normalized gene counts were
generated using Gencodev19 Transcriptome library. Variance stabilizing
transformations of normalized counts were used as a measure of gene
expression (full details are given in the Supplemental Experimental
Procedures). RNA-seq data from normal tissues were taken from Illumina
Bodymap (ArrayExpress: E-MTAB-513 and E-MTAB-2836). Full details for
immunohistochemistry analysis are provided in the Supplemental Experi-
mental Procedures.Statistical Methods
Experimental results are representative of at least three independent experi-
ments. The statistical significance of data in all figures was evaluated by Stu-
dent’s t test. Statistical analysis between combination and single treatment
(Figure 3D) was done by ANOVAwith Tukey’smultiple comparison test. Calcu-
lations were performed with GraphPad Prism software.ACCESSION NUMBERS
The accession numbers for the microarray gene expression data and the array
CGH data reported in this paper are GEO: GSE78864 and GSE87208,
respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
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